Analyze the Cardiovascular Benefits of the Different GLP-1 Agonists
August 2019
Dulaglutide (Trulicity) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.
It joins semaglutide (Ozempic) and liraglutide (Victoza). All three lower CV risk in type 2 patients with CV disease or at high CV risk.
Each of these meds also seems to slow progression to albuminuria...but none have been shown to delay dialysis.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote